News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–18
Matches
18
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

18 matching headlines

Ticker or company: VX1Main company stories
Clear
Latest

finance.yahoo.com Earnings

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the …

Main company 🇩🇪 Germany
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇩🇪 Germany

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

VX1 main company
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Capital return Main company 🇩🇪 Germany

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …

VX1 main company
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver …

VX1 main company
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇪 Germany

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

VX1 main company
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇩🇪 Germany

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

VX1 main company
Sharemaestro market context Trend signal active 52 weeks +28.3% VX1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context